Filtered By:
Infectious Disease: Gastroenteritis
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date.
Order by Relevance | Date
Total 45 results found since Jan 2013.
TREMFYA ® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis
SPRING HOUSE, PENNSYLVANIA, March 17, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data, showing that initiation of TREMFYA® (guselkumab) was associated with greater treatment persistencea compared to secukinumab or ixekizumab in bio-naïve and bio-experienced patientsb living with moderate to severe plaque psoriasis (PsO), based on pairwise analysesc of real-world data.[1],[2] Additionally, in a post-hoc analysis of Phase 3 VOYAGE 2 clinical trial results, TREMFYA demonstrated durable clinical efficacy, itch relief and quality-of-life improvements in patients living with scal...
Source: Johnson and Johnson - March 17, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Nanobodies: Robust Miniprotein Binders in Biomedicine
Adv Drug Deliv Rev. 2023 Feb 6:114726. doi: 10.1016/j.addr.2023.114726. Online ahead of print.ABSTRACTVariable domains of heavy chain-only antibodies (VHH), also known as nanobodies (Nbs), are monomeric antigen-binding domains derived from the camelid heavy chain-only antibodies. Nbs are characterized by small size, high target selectivity, and marked solubility and stability, which collectively facilitate high-quality drug development. In addition, Nbs are readily expressed from various expression systems, including E. coli and yeast cells. For these reasons, Nbs have emerged as preferred antibody fragments for protein en...
Source: Advanced Drug Delivery Reviews - February 8, 2023 Category: Drugs & Pharmacology Authors: Jeffrey Yong Joon Kim Zhe Sang Yufei Xiang Zhuolun Shen Yi Shi Source Type: research
TREMFYA ®▼ (guselkumab) Demonstrates Higher Rates of Complete Skin Clearance with Earlier Treatment in Adults with Moderate to Severe Plaque Psoriasis in Phase 3b GUIDE Study
Beerse, Belgium, 8 September 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data for TREMFYA®▼(guselkumab) from the ongoing Phase 3b GUIDE study, which is designed to understand the impact of early intervention and potential dosing interval flexibility on the long-term disease course in adult patients with moderate to severe plaque psoriasis (Pso). These new data demonstrated that “super responders”a to guselkumab who received every-16-week dosingb maintained disease control (absolute Psoriasis Area and Severity Index [PASI] score <3) at a rate that was non-inferior to ...
Source: Johnson and Johnson - September 8, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Combination of ultrasound-peracetic acid washing and ultrasound-assisted aerosolized ascorbic acid: A novel rinsing-free disinfection method that improves the antibacterial and antioxidant activities in cherry tomato
In this study, we proposed a novel US-assisted hurdle technology of 80 ppm PAA combined with low-frequency US (25 kHz) during washing, followed by US-assisted aerosolization processing (nonimmersion coating). Ascorbic acid (AA), a safe and low-cost agent, was selected as the aerosolization solution. Cherry tomatoes were selected as the model, and the proposed method was compared with traditional US-assisted disinfection methods (US-10 ppm free chlorine washing + TW rinsing and US-5 ppm chlorine dioxide washing + TW rinsing) to analyze the disinfection efficacy and quality changes. During storage, US-PAA + 1%AA facilitated ...
Source: Ultrasonics Sonochemistry - April 11, 2022 Category: Chemistry Authors: Jiayi Wang Zhaoxia Wu Hongbin Wang Source Type: research
Prevalence of Listeria monocytogenes and indicator microorganisms in Florida cantaloupe packinghouses, 2013-2014
Food Microbiol. 2022 Jun;104:103970. doi: 10.1016/j.fm.2021.103970. Epub 2021 Dec 17.ABSTRACTPrior to the 2013 cantaloupe season, the US Food and Drug Administration notified the industry that inspections of a subset of packinghouses would commence that year in response to the 2011 Listeria monocytogenes outbreak associated with cantaloupe. In May 2013, five Florida cantaloupe packinghouses participated in an environmental monitoring survey to evaluate their sanitary conditions prior to a potential FDA inspection. Two facilities participated again in 2014. Surface swabs (n = 374) were collected in each facility and include...
Source: Food Microbiology - March 15, 2022 Category: Food Science Authors: Laurel L Dunn Loretta M Friedrich Laura K Strawn Michelle D Danyluk Source Type: research
